Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA

NCT00002767 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00002767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 1996
Completion date
Not reported
Enrollment
300 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)